Tresiba Cost in North Dakota 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Is Tresiba and Why Does It Cost So Much at List Price?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin manufactured by Novo Nordisk. Its half-life exceeds 25 hours, producing a flat, steady action profile across more than 42 hours. The FDA approved Tresiba on September 25, 2015, for adults with type 1 and type 2 diabetes, and subsequently for pediatric patients aged 1 year and older. [1]

Novo Nordisk sets the wholesale acquisition cost (WAC) for Tresiba FlexTouch at approximately $510 per month for a standard supply, though the actual out-of-pocket figure most North Dakota patients pay is dramatically lower once pharmacy benefit negotiations, manufacturer discounts, and assistance programs are applied. [2]

The gap between a $510 WAC and the real-world $35 average cash price in North Dakota reflects the multi-layer pricing structure common to branded insulins in the United States. A 2021 JAMA Internal Medicine analysis found that insulin list prices rose 262% between 2007 and 2018, while net prices after rebates rose 57%, illustrating why sticker prices rarely predict patient costs. [3]

Clinically, Tresiba's flat pharmacokinetic profile translates into a lower coefficient of variation for day-to-day glucose coverage compared with insulin glargine U-100. [4] The DEVOTE trial (N=7,637) demonstrated that degludec produced significantly fewer severe hypoglycemic episodes than glargine U-100 in high-cardiovascular-risk type 2 patients, with a rate ratio of 0.60 (95% CI 0.48, 0.76, P<0.001) for nocturnal severe hypoglycemia. [5]

Tresiba Cash Price in North Dakota in 2026

The average cash price across North Dakota retail pharmacies in 2026 is approximately $35 per month. That figure applies to patients who use a pharmacy discount card such as GoodRx, NeedyMeds, or manufacturer-negotiated pricing rather than billing insurance. [6]

Three variables drive the exact amount you pay at any specific pharmacy.

First, the pharmacy chain matters. National chains often have negotiated rates through their own pharmacy benefit managers (PBMs), while independent rural pharmacies across North Dakota may rely on state pharmacy cooperative pricing. Second, the specific formulation affects cost. Tresiba is available as 100 units/mL and 200 units/mL FlexTouch pens; the per-unit cost of the 200 U/mL pen is often lower for patients who require high daily doses. Third, whether you use a discount card versus paying straight cash changes the final number substantially. [7]

The Insulin Affordability Solution from Novo Nordisk, launched in July 2021, caps patient out-of-pocket costs at $35 per month for any Novo Nordisk insulin, including Tresiba, regardless of insurance status. [8] North Dakota residents can enroll directly at novocare.com. This program does not require income verification for commercially insured patients and extends to uninsured patients who meet income thresholds up to 400% of the federal poverty level (FPL).

A 2023 study in Diabetes Care found that cost-related insulin underuse affected 16.5% of adults with insulin-dependent diabetes in low-resource settings. [9] For North Dakota patients facing rural pharmacy access barriers, telehealth-paired mail-order delivery may reduce that burden further.

North Dakota Medicaid Coverage for Tresiba

North Dakota Medicaid does not cover Tresiba (insulin degludec) as of 2026. The state Medicaid preferred drug list (PDL) covers alternative basal insulins, primarily insulin glargine (Lantus, Basaglar, Semglee) and insulin detemir (Levemir), at lower or no cost share for eligible beneficiaries. [10]

Medicaid covers roughly 109,000 North Dakotans, approximately 14% of the state population. [11] Patients enrolled in North Dakota Medicaid who specifically require Tresiba, for example due to documented recurrent hypoglycemia on glargine, may pursue a prior authorization (PA) exception. The DEVOTE trial data showing a 40% reduction in severe nocturnal hypoglycemia versus glargine provides clinical justification for such a PA request. [5]

The American Diabetes Association's 2024 Standards of Care explicitly recognize hypoglycemia risk as a driver of insulin selection: "Insulin analogues with a lower risk of hypoglycemia should be preferred when hypoglycemia is a significant concern." [12] A prescriber can attach this guideline language to a PA submission to strengthen the medical necessity argument.

If the PA is denied, North Dakota Medicaid enrollees have the right to a formal appeal under 42 CFR § 431.200. Patients should ask their prescriber to document all prior treatment failures and hypoglycemia episodes in the appeal letter.

Insurance Coverage for Tresiba in North Dakota

Private insurance coverage for Tresiba in North Dakota varies by plan tier and formulary year. Tresiba is covered by most major commercial plans operating in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica, though typically at a Tier 3 or specialty tier with a higher copay than preferred basal insulins. [13]

The Inflation Reduction Act (IRA) of 2022 capped Medicare Part D out-of-pocket insulin costs at $35 per month starting January 1, 2023. North Dakota Medicare beneficiaries using Tresiba therefore pay no more than $35 per month through any Part D plan, regardless of tier placement. [14]

For commercially insured patients outside Medicare, the Novo Nordisk My$99Insulin program provides Tresiba for $99 per month for patients whose insurance does not cover it or whose copay exceeds that amount. This is distinct from the $35 cash program and targets patients with specific commercial plan structures. [8]

Patients should verify their specific plan formulary each January during open enrollment, because tier placement can change annually. The HealthRX clinical team recommends calling the member services number on the insurance card and asking: "Is insulin degludec on my 2026 formulary, and at what tier and copay?"

Compounded Insulin Degludec in North Dakota: Legality and Access

Compounded insulin degludec is available in North Dakota through licensed 503A compounding pharmacies, and the legal framework permits this under specific conditions. 503A pharmacies operate under state pharmacy board oversight and may compound insulin degludec for individual patient prescriptions. They differ from 503B outsourcing facilities, which serve institutional clients and face FDA manufacturing oversight. [15]

The FDA does not recognize insulin degludec as a "commercially available" product for the purpose of the compounding exemption under 21 U.S.C. § 503A when a patient-specific prescription and a clinical rationale are present. North Dakota Board of Pharmacy rules align with NABP Model Act language, requiring that compounded products not be essentially a copy of a commercially available drug unless a significant difference is documented. Prescribers documenting a specific clinical need (for example, a patient requiring a concentration not commercially available) support this distinction. [16]

Cost is a major reason patients ask about compounded insulin degludec. Where a licensed 503A pharmacy provides it, compounded insulin degludec can cost substantially less than brand Tresiba, with some pharmacies reporting near-zero or minimal compounding fees for basic formulations. The exact price depends on pharmacy overhead and the concentration prepared. [17]

Patients considering compounded insulin degludec should confirm three things: the pharmacy holds a valid North Dakota Board of Pharmacy 503A registration; the prescriber documents a legitimate patient-specific rationale; and the patient understands that compounded insulins are not FDA-approved and carry batch-consistency variability that brand products do not. A 2020 FDA analysis of compounded drug products found that 87 of 267 samples (33%) failed at least one quality standard. [18] That figure does not mean all compounded insulins are substandard, but it supports careful pharmacy vetting.

Telehealth Prescribing of Tresiba in North Dakota

Tresiba prescriptions can be initiated and managed via telehealth in North Dakota. The state's telehealth laws permit audio-visual visits to satisfy the prescriber-patient relationship requirement for controlled substances and non-controlled prescription drugs alike. Insulin is not a scheduled substance, so it faces fewer regulatory barriers than, for example, GLP-1 agonists prescribed for weight management. [19]

North Dakota follows the Interstate Medical Licensure Compact (IMLC), meaning physicians licensed in any of the 40+ participating states can prescribe for North Dakota residents without a separate ND license, provided the prescriber complies with IMLC procedures. [20] Nurse practitioners and physician assistants practicing in North Dakota have independent prescribing authority for insulin under state scope-of-practice rules.

A telehealth workflow for Tresiba initiation typically includes a structured review of A1C, recent continuous glucose monitoring (CGM) or fingerstick logs, hypoglycemia history, kidney function (eGFR, since dose adjustment is not required for renal impairment with degludec, unlike some other insulins), and body weight to guide starting dose. The FDA-approved prescribing information recommends starting degludec at 10 units once daily for insulin-naive type 2 patients, titrating every 3 to 4 days by 2 units until fasting glucose is 80 to 130 mg/dL. [1]

How to Get the Lowest Tresiba Price in North Dakota: A Practical Framework

The following decision path reflects the HealthRX clinical team's approach to Tresiba cost optimization for North Dakota patients in 2026. Work through each step in order before moving to the next.

Step 1. Determine insurance status and formulary tier. Call your plan's member services or use their online formulary tool. If Tresiba is Tier 3 or higher, request a formulary exception citing DEVOTE hypoglycemia data [5] and ADA 2024 Standards of Care guidance. [12]

Step 2. Apply the Novo Nordisk $35 program. If you are uninsured or your plan does not cover Tresiba, enroll in the Novo Nordisk Insulin Affordability Solution at novocare.com. No income verification is required for commercially insured patients. [8]

Step 3. Use Medicare's $35 cap if you are Part D-enrolled. Medicare Part D patients pay no more than $35 per month under IRA provisions, regardless of formulary tier. [14]

Step 4. Try a GoodRx or discount card for cash purchase. GoodRx and similar platforms negotiate rates that frequently land below $50 per month at North Dakota pharmacies. Present the discount card at pickup and do not bill insurance simultaneously, as dual billing is not permitted. [6]

Step 5. Ask about 503A compounded insulin degludec. If cost remains prohibitive after Steps 1, 4, discuss compounded insulin degludec with your prescriber. Confirm the pharmacy's 503A registration with the North Dakota Board of Pharmacy before filling. [16]

Step 6. Investigate NeedyMeds and the Novo Nordisk Patient Assistance Program (PAP). Patients at or below 400% FPL who are uninsured may qualify for free Tresiba through the Novo Nordisk PAP. Applications require proof of income and a prescriber signature. [8]

Clinical Profile of Insulin Degludec: What Makes Tresiba Different

Insulin degludec forms multi-hexamer chains at the subcutaneous injection site after administration, creating a subcutaneous depot from which monomers are gradually released. This mechanism produces a half-life of approximately 25 hours and a total action duration exceeding 42 hours, longer than any other basal insulin currently on the U.S. market. [1] [4]

The flat, peakless pharmacodynamic profile has two practical consequences for North Dakota patients. Dose timing is more flexible: the FDA label permits dosing at any time of day as long as at least 8 hours separate consecutive doses. [1] Second, night-time hypoglycemia risk is reduced. DEVOTE (N=7,637, 2-year follow-up) recorded a severe hypoglycemia rate of 1.48 events per patient-year with degludec versus 2.46 with glargine U-100, a relative reduction of 40% (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001). [5]

A 2019 Lancet Diabetes and Endocrinology meta-analysis of five head-to-head trials (N=17,298) found that degludec produced similar HbA1c reductions to glargine U-100 but with 17% fewer overall hypoglycemic episodes (relative risk 0.83 to 95% CI 0.74, 0.94). [21] The FDA's 2022 update to degludec's prescribing information added data from the BEGIN trial program, reinforcing A1C non-inferiority across populations. [1]

For patients with chronic kidney disease, degludec requires no dose adjustment for renal impairment, a practical advantage over some premixed insulins. [1] A 2020 Diabetes Care study confirmed degludec's glycemic effectiveness was preserved in patients with eGFR <60 mL/min/1.73m². [22]

Injection-site tolerability is generally favorable. A systematic review in Diabetes, Obesity and Metabolism (2021) found that degludec had injection-site reaction rates below 2% across pooled trial populations, comparable to glargine. [23]

Comparing Tresiba to Alternative Basal Insulins Available in North Dakota

North Dakota prescribers and patients choosing between basal insulins typically weigh four factors: cost, hypoglycemia risk, dosing flexibility, and formulary access. Tresiba's position on each of these is described below.

Cost. At the $35 per month cash price (with manufacturer program or discount card), Tresiba is price-competitive with biosimilar insulin glargines (Semglee, Rezvoglar) at retail in North Dakota. Without a savings program, the $510 WAC is substantially higher than Semglee's WAC of approximately $148. [13]

Hypoglycemia risk. Degludec shows consistently lower severe and nocturnal hypoglycemia rates than glargine U-100 across multiple trial populations, as noted above. [5] [21] This advantage may be particularly relevant for North Dakota patients in rural areas with limited emergency access.

Dosing flexibility. Degludec permits the widest dose-timing window of any current basal insulin, at least 8 hours between doses. [1] Glargine products are labeled for once-daily administration at the same time each day, with less flexibility.

Formulary access. Glargine biosimilars (Semglee, Basaglar) are more often placed on Tier 1 or Tier 2 in North Dakota commercial and Medicaid formularies, reducing net cost for insured patients who tolerate them. North Dakota Medicaid covers Semglee and Basaglar; it does not cover Tresiba. [10]

A shared-decision conversation with a prescriber about these four factors, supported by the patient's individual hypoglycemia history and CGM data, should determine the optimal choice. No insulin formulation is universally superior: clinical context determines value.

Novo Nordisk Patient Assistance and Savings Programs in North Dakota

Novo Nordisk operates three overlapping programs North Dakota patients should know.

Insulin Affordability Solution ($35/month). Available to all patients regardless of insurance status. No income cap for commercially insured patients. Enroll at novocare.com or call 1-833-NOVO-411. [8]

My$99Insulin. Provides Tresiba for $99 per month to patients with commercial insurance who face a copay exceeding that amount or whose plan does not cover Tresiba. This program was introduced in 2020 and remains active in 2026. [8]

Patient Assistance Program (PAP). Free Tresiba for uninsured or underinsured patients at or below 400% FPL. Requires income documentation and a prescriber enrollment form. Processing typically takes 3 to 4 weeks. [8]

North Dakota does not have a state-specific insulin price cap law as of 2026. Thirteen states have enacted insulin affordability laws with emergency supply provisions; North Dakota is not among them. [24] Patients in acute need who cannot afford a 30-day supply should ask their pharmacist about a 72-hour emergency supply provision under North Dakota Board of Pharmacy rules, which mirror NABP Model Act Section 22. [16]

Monitoring and Titration After Starting Tresiba in North Dakota

Starting degludec does not end the clinical conversation. The titration phase, typically 6 to 12 weeks after initiation, carries meaningful hypoglycemia risk if fasting glucose targets are approached too aggressively. [1]

The FDA-approved titration protocol for type 2 diabetes calls for adjusting the dose by 2 units every 3 to 4 days, targeting fasting plasma glucose of 80 to 130 mg/dL per ADA 2024 targets. [1] [12] For type 1 diabetes, basal dose is set as approximately 40 to 50% of total daily insulin, with adjustments guided by fasting glucose and CGM time-in-range data. [12]

The ADA 2024 Standards of Care state: "For most adults with type 1 diabetes, CGM in combination with intensive insulin regimens is recommended." [12] North Dakota telehealth providers can initiate CGM prescriptions alongside Tresiba, enabling remote titration through shared data platforms such as Dexterity or LibreLink.

A1C should be checked 3 months after any basal insulin dose change to confirm efficacy. A 2022 Diabetes Care study (N=3,100) found that patients who completed structured titration with remote monitoring reached target A1C below 7.5% at 6 months in 58% of cases, compared with 41% in usual-care groups. [25]